Salivary mucins in host defense and disease prevention

Journal of Oral Microbiology

Volumn 7, Issue 1, 2015, Pages

  Frenkel, Erica Shapiro ^a,b   Ribbeck, Katharina ^b  

^a HARVARD UNIVERSITY   (United States)

^b Massachusetts Institute of Technology   (United States)

Author keywords

MUC5B; MUC7; mucin; oral health; saliva

Indexed keywords

EID: 85078811298     PISSN: None     EISSN: 20002297     Source Type: Journal    
DOI: 10.3402/jom.v7.29759     Document Type: Article

References (98)

1. Van der Sluis M, De Koning B, De Bruijn A, Velcich A, Meijerink J, Van Goudoever J, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-29.
2. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, et al. Muc5b is required for airway defence. Nature 2014; 505: 412-16.
3. Brown LR, Dreizen S, Handler S, Johnston DA. Effect of Radiation-induced xerostomia on human oral microflora. J Dent Res 1975; 54: 740-50.
4. Leone CW, Oppenheim FG. Physical and chemical aspects of saliva as indicators of risk for dental caries in humans. J Dent Educ 2001; 65: 1054-62.
5. Ueta E, Tanida T, Doi S, Osaki T. Regulation of Candida albicans growth and adhesion by saliva. J Lab Clin Med 2000; 136: 66-73.
6. Turner MD, Ship JA. Dry mouth and its effects on theoral health of elderly people. J Am Dent Assoc 2007; 138(Suppl 1): S15-20.
7. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. Mucins in the mucosal barrier to infection. Mucosal Immunol 2008; 1: 183-97.
8. Nielsen PA, Bennett EP, Wandall HH, Therkildsen MH, Hannibal J, Clausen H. Identification of a major human high molecular weight salivary mucin (MG1) as tracheobronchial mucin MUC5B. Glycobiology 1997; 7: 413-19.
9. Thornton DJ, Khan N, Mehrotra R, Howard M, Sheehan JK, Veerman E, et al. Salivary mucin MG1 is comprised almost entirely of different glycosylated forms of the MUC5B gene product. Glycobiology 1999; 9: 293-302.
10. Culp DJ, Robinson B, Cash MN, Bhattacharyya I, Stewart C, Cuadra-Saenz G. Salivary mucin 19 glycoproteins: innate immune functions in Streptococcus mutans-induced caries in mice and evidence for expression in human saliva. J Biol Chem 2015; 290: 2993-3008.
11. Rousseau K, Kirkham S, Johnson L, Fitzpatrick B, Howard M, Adams EJ, et al. Proteomic analysis of polymeric salivary mucins: no evidence for MUC19 in human saliva. Biochem J 2008; 413: 545-52.
12. Chen Y, Zhao YH, Kalaslavadi TB, Hamati E, Nehrke K, Le AD, et al. Genome-wide search and identification of a novel gel-forming mucin MUC19/Muc19 in glandular tissues. Am J Respir Cell Mol Biol 2004; 30: 155-65.
13. Mehrotra R, Thornton DJ, Sheehan JK. Isolation and physical characterization of the MUC7 (MG2) mucin from saliva: evidence for self-association. Biochem J 1998; 334: 415-22.
14. Piludu M, Rayment SA, Liu B, Offner GD, Oppenheim FG, Troxler RF, et al. Electron microscopic immunogold localization of salivary mucins MG1 and MG2 in human submandibular and sublingual glands. J Histochem Cytochem 2003; 51: 69-79.
15. Liu B, Lague JR, Nunes DP, Toselli P, Oppenheim FG, Soares RV, et al. Expression of membrane-associated mucins MUC1 and MUC4 in major human salivary glands. J Histochem Cytochem 2002; 50: 811-20.
16. Sengupta A, Valdramidou D, Huntley S, Hicks SJ, Carrington SD, Corfield AP. Distribution of MUC1 in the normal human oral cavity is localized to the ducts of minor salivary glands. Arch Oral Biol 2001; 46: 529-38.
17. Offner GD, Troxler RF. Heterogeneity of high-molecular-weight human salivary mucins. Adv Dent Res 2000; 14: 69-75.
18. Parmley RR, Gendler SJ. Cystic fibrosis mice lacking Muc1 have reduced amounts of intestinal mucus. J Clin Invest 1998; 102: 1798-806.
19. Gabryel-Porowska H, Gornowicz A, Bielawska A, Wójcicka A, Maciorkowska E, Grabowska SZ, et al. Mucin levels in saliva of adolescents with dental caries. Med Sci Monit 2014; 20: 72-7.
20. Desseyn J-L, Aubert J-P, Porchet N, Laine A. Evolution of the large secreted gel-forming mucins. Mol Biol Evol 2000; 17: 1175-84.
21. Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 2006; 1765: 189-222.
22. Gururaja TL, Ramasubbu N, Venugopalan P, Reddy MS, Ramalingam K, Levine MJ. Structural features of the human salivary mucin, MUC7. Glycoconj J 1998; 15: 457-67.
23. Moniaux N, Escande F, Porchet N, Aubert JP, Batra SK. Structural organization and classification of the human mucin genes. Front Biosci 2001; 6: D1192-206.
24. Bork P, Patthy L. The SEA module: a new extracellular domain associated with O-glycosylation. Protein Sci 1995; 4: 1421-5.
25. Choudhury A, Moniaux N, Ringel J, King J, Moore E, Aubert J-P, et al. Alternate splicing at the 3?-end of the human pancreatic tumor-associated mucin MUC4 cDNA. Teratog Carcinog Mutagen 2001; 21: 83-96.
26. Thomsson KA, Prakobphol A, Leffler H, Reddy MS, Levine MJ, Fisher SJ, et al. The salivary mucin MG1 (MUC5B) carries a repertoire of unique oligosaccharides that is large and diverse. Glycobiology 2002; 12: 1-14.
27. Amerongen AVN, Bolscher JGM, Veerman ECI. Salivary mucins: protective functions in relation to their diversity. Glycobiology 1995; 5: 733-40.
28. Zalewska A, Zwierz K, Zółkowski K, Gindzieński A. Structure and biosynthesis of human salivary mucins. Acta Biochim Pol 2000; 47: 1067-79.
29. Strous GJ, Dekker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol 1992; 27: 57-92.
30. Desseyn JL, Aubert JP, Van Seuningen I, Porchet N, Laine A. Genomic organization of the 3’ region of the human mucin gene MUC5B. J Biol Chem 1997; 272: 16873-83.
31. Kesimer M, Makhov AM, Griffith JD, Verdugo P, Sheehan JK. Unpacking a gel-forming mucin: a view of MUC5B organization after granular release. Am J Physiol-Lung Cell Mol Physiol 2010; 298: L15-22.
32. Preciado D, Goyal S, Rahimi M, Watson AM, Brown KJ, Hathout Y, et al. MUC5B is the predominant mucin glycopro-tein in chronic otitis media fluid. Pediatr Res 2010; 68: 231-6.
33. Perez-Vilar J, Eckhardt AE, DeLuca A, Hill RL. Porcine submaxillary mucin forms disulfide-linked multimers through its amino-terminal D-domains. J Biol Chem 1998; 273: 14442-9.
34. Perez-Vilar J, Eckhardt AE, Hill RL. Porcine submaxillary mucin forms disulfide-bonded dimers between its carboxyl-terminal domains. J Biol Chem 1996; 271: 9845-50.
35. Adler KB, Tuvim MJ, Dickey BF. Regulated mucin secretion from airway epithelial cells. Neuroendocr Sci 2013; 4: 129.
36. Perez-Vilar J, Hill RL. The structure and assembly of secreted mucins. J Biol Chem 1999; 274: 31751-4.
37. Perez-Vilar J, Mabolo R. Gel-forming mucins. Notions from in vitro studies. Histol Histopathol 2007; 22: 455-64.
38. Ridley C, Kouvatsos N, Raynal BD, Howard M, Collins RF, Desseyn J-L, et al. Assembly of the respiratory mucin MUC5B: a new model for a gel-forming mucin. J Biol Chem 2014; 289: 16409-20.
39. Perez-Vilar J. Mucin granule intraluminal organization. Am J Respir Cell Mol Biol 2007; 36: 183-90.
40. Verdugo P. Goblet cells secretion and mucogenesis. Annu Rev Physiol 1990; 52: 157-76.
41. Bromberg LE, Barr DP. Self-association of mucin. Biomacro-molecules 2000; 1: 325-34.
42. Soby LM, Jamieson AM, Blackwell J, Jentoft N. Viscoelastic properties of solutions of ovine submaxillary mucin. Biopoly-mers 1990; 29: 1359-66.
43. McCullagh CM, Jamieson AM, Blackwell J, Gupta R. Viscoe-lastic properties of human tracheobronchial mucin in aqueous solution. Biopolymers 1995; 35: 149-59.
44. Raynal BDE, Hardingham TE, Sheehan JK, Thornton DJ. Calcium-dependent protein interactions in MUC5B provide reversible cross-links in salivary mucus. J Biol Chem 2003; 278: 28703-10.
45. Al-Hashimi I, Levine MJ. Characterization of in vivo salivary-derived enamel pellicle. Arch Oral Biol 1989; 34: 289-95.
46. Cárdenas M, Elofsson U, Lindh L. Salivary mucin MUC5B could be an important component of in vitro pellicles of human saliva: An in situ ellipsometry and atomic force microscopy study. Biomacromolecules 2007; 8: 1149-56.
47. Bobek LA, Tsai H, Biesbrock AR, Levine MJ. Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7). J Biol Chem 1993; 268: 20563-9.
48. Bansil R, Turner BS. Mucin structure, aggregation, physio-logical functions and biomedical applications. Curr Opin Colloid Interface Sci 2006; 11: 164-70.
49. Tabak LA. Structure and function of human salivary mucins. Crit Rev Oral Biol Med 1990; 1: 229-34.
50. Tabak LA, Levine MJ, Mandel ID, Ellison SA. Role of salivary mucins in the protection of the oral cavity. J Oral Pathol 1982; 11: 1-17.
51. Tabak LA. In defense of the oral cavity: structure, biosynthesis, and function of salivary mucins. Annu Rev Physiol 1995; 57: 547-64.
52. Levine MJ, Reddy MS, Tabak LA, Loomis RE, Bergey EJ, Jones PC, et al. Structural aspects of salivary glycoproteins. J Dent Res 1987; 66: 436-41.
53. Bruno LS, Li X, Wang L, Soares RV, Siqueira CC, Oppenheim FG, et al. Two-hybrid analysis of human salivary mucin MUC7 interactions. Biochim Biophys Acta 2005; 1746: 65-72.
54. Iontcheva I, Oppenheim FG, Troxler RF. Human salivary mucin MG1 selectively forms heterotypic complexes with amylase, proline-rich proteins, statherin, and histatins. J Dent Res 1997; 76: 734-43.
55. Gibbins HL, Proctor GB, Yakubov GE, Wilson S, Carpenter GH. SIgA binding to mucosal surfaces is mediated by mucin-mucin interactions. PLoS One 2015; 10: e0119677.
56. Koop HM, Valentijn-Benz M, Nieuw Amerongen AV, Roukema PA, de Graaff J. Involvement of human mucous saliva and salivary mucins in the aggregation of the oral bacteria Streptococcus sanguis, Streptococcus oralis, and Streptococcus rattus. Antonie Van Leeuwenhoek 1990; 57: 245-52.
57. Gibbons RJ, Cohen L, Hay DI. Strains of Streptococcus mutans and Streptococcus sobrinus attach to different pellicle receptors. Infect Immun 1986; 52: 555-61.
58. Gibbons RJ, Qureshi JV. Selective binding of blood group-reactive salivary mucins by Streptococcus mutans and other oral organisms. Infect Immun 1978; 22: 665-71.
59. Levine MJ, Herzberg MC, Levine MS, Ellison SA, Stinson MW, Li HC, et al. Specificity of salivary-bacterial interactions: role of terminal sialic acid residues in the interaction of salivary glycoproteins with Streptococcus sanguis and Streptococcus mutans. Infect Immun 1978; 19: 107-15.
60. Williams RC, Gibbons RJ. Inhibition of streptococcal attach-ment to receptors on human buccal epithelial cells by anti-genically similar salivary glycoproteins. Infect Immun 1975; 11: 711-18.
61. Murray PA, Levine MJ, Tabak LA, Reddy MS. Specificity of salivary-bacterial interactions: II. Evidence for a lectin on Streptococcus sanguis with specificity for a NeuAc alpha 2, 3Ga1 beta 1, 3Ga1NAc sequence. Biochem Biophys Res Commun 1982; 106: 390-6.
62. Murray PA, Prakobphol A, Lee T, Hoover CI, Fisher SJ. Adherence of oral streptococci to salivary glycoproteins. Infect Immun 1992; 60: 31-8.
63. Ligtenberg AJ, Walgreen-Weterings E, Veerman EC, de Soet JJ, de Graaff J, Amerongen AV. Influence of saliva on aggregation and adherence of Streptococcus gordonii HG 222. Infect Immun 1992; 60: 3878-84.
64. Plummer C, Douglas CWI. Relationship between the ability of oral streptococci to interact with platelet glycoprotein Ibalpha and with the salivary low-molecular-weight mucin, MG2. FEMS Immunol Med Microbiol 2006; 48: 390-9.
65. Stinson MW, Levine MJ, Cavese JM, Prakobphol A, Murray PA, Tabak LA, et al. Adherence of Streptococcus sanguis to salivary mucin bound to glass. J Dent Res 1982; 61: 1390-3.
66. Takamatsu D, Bensing BA, Prakobphol A, Fisher SJ, Sullam PM. Binding of the streptococcal surface glycoproteins GspB and Hsa to human salivary proteins. Infect Immun 2006; 74: 1933-40.
67. Kesimer M, Kiliç N, Mehrotra R, Thornton DJ, Sheehan JK. Identification of salivary mucin MUC7 binding proteins from Streptococcus gordonii. BMC Microbiol 2009; 9: 163.
68. Moshier A, Reddy MS, Scannapieco FA. Role of type 1 fimbriae in the adhesion of Escherichia coli to salivary mucin and secretory immunoglobulin A. Curr Microbiol 1996; 33: 200-8.
69. Heo S-M, Choi K-S, Kazim LA, Reddy MS, Haase EM, Scannapieco FA, et al. Host defense proteins derived from human saliva bind to Staphylococcus aureus. Infect Immun 2013; 81: 1364-73.
70. Bradway SD, Bergey EJ, Scannapieco FA, Ramasubbu N, Zawacki S, Levine MJ. Formation of salivary-mucosal pellicle: the role of transglutaminase. Biochem J 1992; 284: 557-64.
71. Gibbins H, Proctor G, Yakubov G, Wilson S, Carpenter G. Concentration of salivary protective proteins within the bound oral mucosal pellicle. Oral Dis 2014; 20: 707-13.
72. Veerman EC, Ligtenberg AJ, Schenkels LC, Walgreen-Weterings E, Nieuw Amerongen AV. Binding of human high-molecular-weight salivary mucins (MG1) to Hemophilus parainfluenzae. J Dent Res 1995; 74: 351-7.
73. Namavar F, Sparrius M, Veerman EC, Appelmelk BJ, Vandenbroucke-Grauls CM. Neutrophil-activating protein mediates adhesion of Helicobacter pylori to sulfated carbohydrates on high-molecular-weight salivary mucin. Infect Immun 1998; 66: 444-7.
74. Frenkel ES, Ribbeck K. Salivary mucins protect surfaces from colonization by cariogenic bacteria. Appl Environ Microbiol 2015; 81: 332-8.
75. Phillips J, Qureshi N, Barr C, Henrard DR. Low level of cell-free virus detected at high frequency in saliva from HIV-1-infected individuals. AIDS 1994; 8: 1011-12.
76. Wahl SM, Worley P, Jin W, McNeely TB, Eisenberg S, Fasching C, et al. Anatomic dissociation between HIV-1 and its endo-genous inhibitor in mucosal tissues. Am J Pathol 1997; 150: 1275-84.
77. Fultz PN, McClure HM, Daugharty H, Brodie A, McGrath CR, Swenson B, et al. Vaginal transmission of human im-munodeficiency virus (HIV) to a chimpanzee. J Infect Dis 1986; 154: 896-900.
78. Archibald DW, Cole GA. In vitro inhibition of HIV-1 infecti-vity by human salivas. AIDS Res Hum Retroviruses 1990; 6: 1425-32.
79. Bergey EJ, Cho MI, Blumberg BM, Hammarskjöld ML, Rekosh D, Epstein LG, et al. Interaction of HIV-1 and human salivary mucins. J Acquir Immune Defic Syndr 1994; 7: 995-1002.
80. Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein LT, Malamud D. Human submandibular saliva speci-fically inhibits HIV type 1. AIDS Res Hum Retroviruses 1997; 13: 371-6.
81. Habte HH, Mall AS, Beer C de, Lotz ZE, Kahn D. The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay. Virol J 2006; 3: 99.
82. Peacocke J, Lotz Z, Beer C de, Roux P, Mall AS. The role of crude saliva and purified salivary mucins in the inhibition of the Human Immunodeficiency Virus type 1. Virol J 2012; 9: 177.
83. Habte HH, Beer C de, Lotz ZE, Roux P, Mall AS. Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts. Virol J 2010; 7: 269.
84. Zhang N, Zhang Z, Feng S, Wang Q, Malamud D, Deng H. Quantitative analysis of differentially expressed saliva proteins in human immunodeficiency virus type 1 (HIV-1) infected indi-viduals. Anal Chim Acta 2013; 774: 61-6.
85. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984; 311: 354-8.
86. Schelenz S. Management of candidiasis in the intensive care unit. J Antimicrob Chemother 2008; 61(Suppl 1): i31-4.
87. Kavanaugh NL, Zhang AQ, Nobile CJ, Johnson AD, Ribbeck K. Mucins suppress virulence traits of Candida albicans. mBio 2014; 5: e01911-14.
88. Ogasawara A, Komaki N, Akai H, Hori K, Watanabe H, Watanabe T, et al. Hyphal formation of Candida albicans is inhibited by salivary mucin. Biol Pharm Bull 2007; 30: 284-6.
89. Dalle F, Wächtler B, L’Ollivier C, Holland G, Bannert N, Wilson D, et al. Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cell Microbiol 2010; 12: 248-71.
90. Phan QT, Belanger PH, Filler SG. Role of hyphalformation in interactions of Candida albicans with endothelial cells. Infect Immun 2000; 68: 3485-90.
91. Hoffman MP, Haidaris CG. Analysis of Candida albicans adhesion to salivary mucin. Infect Immun 1993; 61: 1940-9.
92. Satyanarayana J, Situ H, Narasimhamurthy S, Bhayani N, Bobek LA, Levine MJ. Divergent solid-phase synthesis and candidacidal activity of MUC7 D1, a 51-residue histidine-rich N-terminal domain of human salivary mucin MUC7. J Pept Res 2000; 56: 275-82.
93. Liu B, Rayment SA, Gyurko C, Oppenheim FG, Offner GD, Troxler RF. The recombinant N-terminal region of human salivary mucin MG2 (MUC7) contains a binding domain for oral streptococci and exhibits candidacidal activity. Biochem J 2000; 345: 557-64.
94. Situ H, Bobek LA. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother 2000; 44: 1485-93.
95. Gururaja TL, Levine JH, Tran DT, Naganagowda GA, Ramalingam K, Ramasubbu N, et al. Candidacidal activity pro-mpted by N-terminus histatin-like domain of human salivary mucin (MUC7)1. Biochim Biophys Acta 1999; 1431: 107-19.
96. Lis M, Bobek LA. Proteomic and metabolic characterization of a Candida albicans mutant resistant to the antimicrobial peptide MUC7 12-mer. FEMS Immunol Med Microbiol 2008; 54: 80-91.
97. Baughan LW, Robertello FJ, Sarrett DC, Denny PA, Denny PC. Salivary mucin as related to oral Streptococcus mutans in elderly people. Oral Microbiol Immunol 2000; 15: 10-14.
98. Ge J, Catt DM, Gregory RL. Streptococcus mutans surface alpha-enolase binds salivary mucin MG2 and human plasminogen. Infect Immun 2004; 72: 6748-52.